Paprotrain

• Description :

  Paprotrain is a cell-permeable inhibitor of the kinesin MKLP-2, inhibits the ATPase activity of MKLP-2 with an IC50 of 1.35 μM and a Ki of 3.36 μM and shows a moderate inhibition activity on DYRK1A with an IC50 of 5.5 μM.

• CAS Number :

  [57046-73-8]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Kinesin

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/Paprotrain.html

• Concentration :

  10mM

• Purity :

  99.87

• Solubility :

  DMSO : ≥ 100 mg/mL

• Smiles :

  N#C/C(C1=CNC2=CC=CC=C21)=C\C3=CN=CC=C3

• Molecular Formula :

  C16H11N3

• Molecular Weight :

  245.28

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Labrière C, et al. Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. Eur J Med Chem. 2016 Nov 29;124:920-934.|[2]Liu J, et al. MKlp2 inhibitor paprotrain affects polar body extrusion during mouse oocyte maturation. Reprod Biol Endocrinol. 2013 Dec 21;11:117.|[3]Zhang Y, et al. KIF20A regulates porcine oocyte maturation and early embryo development.|[4]Tcherniuk S, et al. Relocation of Aurora B and survivin from centromeres to the central spindle impaired by a kinesin-specific MKLP-2 inhibitor. Angew Chem Int Ed Engl. 2010 Oct 25;49 (44) :8228-31.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Kinesin-6